Novo Nordisk A/S – Share repurchase programme
November 09 2020 - 6:49AM
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 9 November 2020 – On 3 November 2020,
Novo Nordisk initiated a share repurchase programme in accordance
with Article 5 of Regulation No 596/2014 of the European Parliament
and Council of 16 April 2014 (MAR) and the Commission Delegated
Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour
Rules"). This programme is part of the overall share repurchase
programme of up to DKK 17 billion to be executed during a 12-month
period beginning 5 February 2020.
Under the programme initiated 3 November 2020, Novo Nordisk will
repurchase B shares for an amount up to DKK 2.7 billion in the
period from 4 November 2020 to 1 February 2021.
Since the announcement of the programme, the following
transactions have been made:
|
Number ofB shares |
Averagepurchase price |
Transactionvalue, DKK |
4 November 2020 |
110,000 |
435.07 |
47,857,532 |
5 November 2020 |
110,000 |
449.10 |
49,401,317 |
6 November 2020 |
110,000 |
452.09 |
49,729,445 |
Accumulated under the programme |
330,000 |
|
146,988,294 |
The details for each transaction made under the share repurchase
programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of
33,866,869 B shares of DKK 0.20 as treasury shares, corresponding
to 1.4% of the share capital. The total amount of A and B shares in
the company is 2,350,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to
DKK 17 billion during a 12-month period beginning 5 February 2020.
As of 6 November 2020, Novo Nordisk has since 5 February 2020
repurchased a total of 33,915,522 B shares at an average share
price of DKK 424.89 per B share equal to a transaction value of DKK
14,410,417,764.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines and working to prevent and ultimately cure disease. Novo
Nordisk employs about 43,100 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media: |
|
|
Anne Margrethe
Hauge |
+45 4442 3450 |
amhg@novonordisk.com |
Ken Inchausti
(US) |
+1 609 240
9429 |
kiau@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
Valdemar Borum
Svarrer |
+45 3079 0301 |
jvls@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
Mark Joseph Root |
+45 3079 4211 |
mjhr@novonordisk.com |
Kristoffer Due Berg
(US) |
+1 609 235
2989 |
krdb@novonordisk.com |
Company announcement No 69 / 2020
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024